BRISBANE, CA – November 13, 2025 — Gate Bioscience announced the closing of an oversubscribed $65 million Series B financing round to advance its oral molecular gate medicines into IND-enabling studies and early-phase clinical development. Led by Forbion with participation from Eli Lilly and several top-tier venture firms, the funding supports Gate’s development of small-molecule agents designed to block the secretion of disease-mediating proteins at their cellular source—introducing a novel class of therapeutics for inflammatory and neurological disorders.
Science Significance
Gate’s molecular gate technology represents a breakthrough in small-molecule drug design. By inhibiting the SEC61 translocon, these compounds prevent pathogenic proteins from entering the secretory pathway, reducing harmful extracellular protein levels. This upstream approach contrasts with traditional biologics and small molecules that act after secretion, offering potential improvements in efficacy, selectivity, and oral dosing convenience. The platform enables targeting previously “undruggable” secreted proteins implicated in chronic diseases.
Regulatory Significance
As a first-in-class modality, molecular gate programs face heightened regulatory expectations around mechanistic validation, safety modelling, and biomarker strategies. The Series B funding allows Gate to expand regulatory readiness, including toxicology studies, pharmacodynamic assays, and manufacturing scale-up under GMP guidance. Early engagement with the FDA regarding trial design, dosing, and translational evidence will shape the IND pathway and future clinical approvals.
Business Significance
Advertisement
The successful Series B round validates investor confidence in Gate’s platform and paves the way for rapid pipeline expansion. The financing strengthens Gate’s ability to progress multiple programs simultaneously, expand its team, and build manufacturing and analytical capabilities. The entry of a strategic pharma investor such as Eli Lilly signals strong commercial interest in the technology, potentially enabling future collaborations and licensing opportunities.
Patients’ Significance
For patients with chronic inflammatory diseases and neurological disorders, molecular gate medicines offer a new treatment paradigm: oral medicines that intervene earlier in the disease process and avoid the burdens of injectable biologics. By targeting secreted proteins at their source, treatment may deliver improved symptom control, reduced flares, and greater access for diverse patient groups.
Policy Significance
Gate’s advancement aligns with policy priorities supporting first-in-class therapeutic innovation, orally accessible treatments, and biotech investment ecosystems. Government and regulatory bodies increasingly encourage modalities that improve affordability and accessibility; oral molecular gates could significantly reduce cost barriers associated with biologics. This modality may influence future reimbursement models and therapeutic guidelines across inflammatory and neurological disease areas.
Gate Bioscience’s $65 million Series B funding marks a transformative step toward delivering molecular gate medicines to the clinic. With a strong scientific foundation, strategic investor support, and a novel therapeutic approach, the company is poised to redefine how secreted-protein-driven diseases are treated.
Source: Gate Bioscience press release
